AI chip startup Cerebras files for IPO
AI chip startup Cerebras has filed for an IPO, signaling significant investor interest in the specialized hardware powering artificial intelligence.
Read on TechCrunch →
Medvolt AI is leveraging OpenAI-enabled intelligence to significantly accelerate the drug discovery process, aiming to reduce experimental cycles and identify promising molecules faster.
Why it matters
This article highlights a crucial application of AI in a high-impact sector: healthcare. By using OpenAI's capabilities to streamline drug discovery, Medvolt AI addresses a long-standing challenge of time, cost, and failure rates in pharmaceutical research. This advancement could lead to faster development of new treatments, potentially saving lives and improving global health outcomes by making life-saving drugs more accessible sooner.
A company called Medvolt AI is using smart AI tools from OpenAI to speed up how new medicines are found. This means they can test ideas faster and pick the best ones more quickly, which could lead to new drugs being available to people much sooner and at a lower cost.
AI chip startup Cerebras has filed for an IPO, signaling significant investor interest in the specialized hardware powering artificial intelligence.
Read on TechCrunch →App store launches are reportedly surging in 2026, with AI tools potentially driving this growth.
Read on TechCrunch →New iPhone app Gigs uses AI to transform users' concert history from digital memorabilia into a personalized live music archive.
Read on TechCrunch →